Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID (31027750)
Authors Mehlman C, Chaabane N, Lacave R, Kerrou K, Ruppert AM, Cadranel J, Fallet V
Title Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
Journal Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Vol 14
Issue 5
Date 2019 05
URL
Abstract Text

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
ALK T1151R missense unknown ALK T1151R lies within the protein kinase domain of the Alk protein (UniProt.org). T1151R has been demonstrated to occur as a secondary drug resistance mutation in the context of ALK rearrangement (PMID: 31027750), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Dec 2022). Y
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK rearrange ALK T1151R lung adenocarcinoma predicted - resistant Ceritinib Case Reports/Case Series Actionable In a clinical case study, ALK T1151R was identified on post-progression biopsy in a patient with lung adenocarcinoma harboring an ALK rearrangement who had been on Zykadia (ceritinib) treatment for 6 months (PMID: 31027750). 31027750
ALK rearrange ALK T1151R lung adenocarcinoma predicted - sensitive Brigatinib Case Reports/Case Series Actionable In a clinical case study, Alunbrig (brigatinib) treatment resulted in clinical improvement and a major response in tumor volume and metabolic activity in a patient with metastatic lung adenocarcinoma harboring an ALK rearrangement and ALK T1151R until disease progression 3 months later (PMID: 31027750). 31027750